logo
logo

Basking Biosciences, Inc. Completes $5.4M Seed Financing

Dec 07, 2020•almost 5 years ago

Amount Raised

$5 Million

Round Type

seed

Columbus

Description

Basking Biosciences, Inc. (Basking), a privately-held biopharmaceutical company developing a next generation treatment for acute ischemic stroke (AIS) announced an initial closing of a $5.4M Seed Series financing. The investor syndicate includes Rev1 Ventures, Broadview Ventures and Viva BioInnovator. Concurrent with the financing, Ryan Helon of Rev1, Thomas Needham of Broadview and Dr

Company Information

Company

Ischemic Stroke

Location

Columbus, Mississippi, United States

About

Over 15 million people worldwide suffer from a stroke each year. With 6 million deaths annually, stroke is the second leading cause of death worldwide after cardiovascular disease and is the leading cause of long-term disability. In the United States, ischemic stroke affects approximately 700,000 people annually and results in 140,000 deaths.